Burnley-Moran and Johnson elementary schools in Charlottesville will have new names at the start of the next school year.

Redwood City and Boston-based Adicet Bio ... formed a collaboration with Sarepta to develop therapies for neuromuscular diseases, which included $57 million in near-term payments.

Paris 2024 Olympics: is open-water swimming in the Seine safe?

Despite temperature cooldown, tick activity is still on the rise, warn officials ...

https://www.tipranks.com/news/the-fly/sarepta-could-be-down-on-patient-death-in-fda-database-says-rbc-capital RBC Capital analyst Brian Abrahams says shares of ...

Tazeen Ahmad, an analyst from Bank of America Securities, maintained the Buy rating on Sarepta Therapeutics (SRPT – Research Report). The associated price target remains the same with $217.00.

Shares of Sarepta (SRPT) are down this morning, potentially due to the latest FDA Adverse Event Reporting System update on Elevidys, which included a patient death from November in a patient who ...

We recently published an article titled Jim Cramer’s Lightning Rounds: 9 Stocks in Focus. In this article, we are going to ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported preliminary* fourth quarter and full-year ...

Sarepta Therapeutics' Elevidys for DMD shows growing revenue potential, with management targeting >$3bn of total revenues in 2025, up 68% from 2024, led by gene therapy. Despite past valuation ...

A report from the U.S. FDA's Office of Inspector General is calling into question the thoroughness of the agency's accelerated approval process, and is using treatments from Sarepta Therapeutics ...